Novartis Gene Therapies’ president, Chris Fox, and team are hyper-focused on newborn screenings as the pathway to helping patients. The company's initial gene therapy, Zolgensma, for SMA has treated more than 2,300 patients worldwide. Fox details what’s next on the commercialization front and shares advice with Cell & Gene: The Podcast listeners about what it takes to commercialize a therapy. Listen now and subscribe so you never miss an episode!
Manufacturers must understand the challenges associated with creating a CMC strategy, and the expertise and resources needed to execute it, in today’s crowded and diverse market.
Article |
By Jakob Bonde and Jacqueline Hargis, Ph.D.,Lonza
CMC activities are critical to quickly and efficiently moving promising new drug products to market. Careful planning and early integration of an effective CMC strategy contributes to project success.
As drug development becomes increasingly expensive and complex, pharma companies are relying on CDMOs. Consider the opportunities and challenges of end-to-end arrangements.
Explore the needs of more complex candidates through case studies that demonstrate the range of expression capabilities across mammalian and microbial derived molecules.
